The mass-action law based algorithms for quantitative econo-green bio-research
The mass-action law based algorithms for quantitative econo-green bio-research
复制标题
DOI：
10.1039/c0ib00130a
复制
发表时间：
2011-01-01
影响因子：
2.5
通讯作者：
Chou, Ting-Chao
中科院分区：
文献类型：
--
作者：
Chou, Ting-Chao
剂量和效应之间的关系不是随机的，而是受基于质量作用定律的中值效应方程（MEE）的统一理论支配。 MEE 的重新排列产生了生物化学和生物物理学的 Michaelis-Menten、Hill、Henderson-Hasselbalch 和 Scatchard 方程的数学形式，并且中值效应图允许所有剂量效应曲线的线性化，无论效力和形状如何。 “中位数”是一阶到高阶动力学、从单实体到多实体的通用公共链接和参考点，因此，它允许一一统一理论“集成”简单和复杂的系统。其应用包括构建剂量效应曲线，如果准确确定的话，理论上最少只有两个数据点；所有剂量和效应水平下的协同或拮抗作用的量化；致癌物、有毒物质或辐射的低剂量风险评估；以及受体结合的竞争性和排他性的确定。由于MEE算法可以减少小规模实验对数据点数量的要求，并产生定量的生物信息学，因此它指向确定性、高效、低成本的生物医学研究和药物发现以及临床试验的伦理规划。结论是，当代生物医学将极大地受益于基于群众行动法的“绿色革命”。
The relationship between dose and effect is not random, but rather governed by the unified theory based on the median-effect equation (MEE) of the mass-action law. Rearrangement of MEE yields the mathematical form of the Michaelis-Menten, Hill, Henderson-Hasselbalch and Scatchard equations of biochemistry and biophysics, and the median-effect plot allows linearization of all dose-effect curves regardless of potency and shape. The "median'' is the universal common-link and reference-point for the 1st-order to higher-order dynamics, and from single-entities to multiple-entities and thus, it allows the all for one and one for all unity theory to "integrate'' simple and complex systems. Its applications include the construction of a dose-effect curve with a theoretical minimum of only two data points if they are accurately determined; quantification of synergism or antagonism at all dose and effect levels; the low-dose risk assessment for carcinogens, toxic substances or radiation; and the determination of competitiveness and exclusivity for receptor binding. Since the MEE algorithm allows the reduced requirement of the number of data points for small size experimentation, and yields quantitative bioinformatics, it points to the deterministic, efficient, low-cost biomedical research and drug discovery, and ethical planning for clinical trials. It is concluded that the contemporary biomedical sciences would greatly benefit from the mass-action law based "Green Revolution''.